Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zingivir-H
Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H
Highest Development Status: Phase IV Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
The studies found that 58 patients treated with the herbo-mineral drug, ZingiVir-H recovered and reported a negative Reverse Transcription Polymerase Chain Reaction (RT-PCR) recovery in an average of five days while others took an average of eight days to recover.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amrta Karuna
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Notable results for the Amrta Karuna treatment group compared to the control showed Significant reduction in hospital quarantine (28% decrease) , Significantly reduced CRP inflammatory levels, RT-PCR negative on day 7 at 71.42% vs 42.85% , TLC within normal range.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: FabiFlu
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team within the country, ensuring self-reliance with regard to longterm production and manufacturing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zingivir-H
Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H
Highest Development Status: Phase IV Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2020
Details:
Clinical trials of ZingiVir-H, Pankajakasthuri’s new drug, are underway among 112 patients as an adjunct therapy for the pandemic as well as among 135 additional patients as a stand-alone treatment in a double-blind study.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
